

MAKE PROTECTION YOUR SUPERPOWER



Not actual patient.



Jardiance®
(empagliflozin)

IS JARDIANCE YOUR #1 CHOICE FOR PATIENTS WITH HEART FAILURE?



In the treatment of patients with HFrEF* and HFpEF†
ADD JARDIANCE EARLY TO REDUCE RISK OF CV DEATH OR HHF^{1,2}



Meet Saleh,
a patient with HFrEF


Across the LVEF spectrum

HFrEF

LVEF ≤ 40%

HFpEF

LVEF > 40%



Meet Fatma,
a patient with HFpEF

← Not actual patient. →


CURRENT CLINICAL PRESENTATION

63 years	← Age →	66 years
NYHA class II	← Experiencing HF symptoms →	Dyspnea; oedema; NYHA class II, progressing to class III

MEDICAL HISTORY

30%-35%	← LVEF →	55%-60%
ARB, diuretic, beta blocker	← Current therapy →	Diuretic
58 mL/min/1.73 m ²	← eGFR →	45 mL/min/1.73 m ²
5' 10"	← Height →	5' 4"
84 kg	← Weight →	64 kg
132/84 mm Hg	← Blood pressure →	140/88 mm Hg

Help protect your patients with HFrEF today! Make JARDIANCE foundational therapy for your patients like Saleh



Help protect your patients with HFpEF today! JARDIANCE is the 1st medicine clinically proven[‡] and approved across the LVEF spectrum¹⁻³

Abbreviations:

ARB=angiotensin II receptor blocker; CKD=chronic kidney disease; CV=cardiovascular; eGFR=estimated glomerular filtration rate; HF=heart failure; HFpEF=heart failure with preserved ejection fraction; HFrEF=heart failure with reduced ejection fraction; HHF=hospitalization for heart failure; LVEF=left ventricular ejection fraction; NYHA>New York Heart Association.

Footnotes:

*Adult patients with chronic heart failure (NYHA class II, III, or IV) and reduced ejection fraction (LVEF ≤ 40%).¹

†Adult patients with chronic heart failure (NYHA class II, III, or IV) and preserved ejection fraction (LVEF > 40%).²

[‡]Proven=meeting the primary endpoint in clinical trials.

References:

1. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med.* 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190 (EMPEROR-Reduced results and the publication's Supplementary Appendix.)

2. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med.* 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 (EMPEROR-Preserved results and the publication's Supplementary Appendix.)

3. JARDIANCE [local summary of product characteristics] July 2023.

Boehringer Ingelheim

Scientific Office

Dubai International Financial Center (DIFC),
Dubai, United Arab Emirates, P.O. Box 507066

For any adverse events please contact Boehringer Ingelheim's responsible Pharmacovigilance unit use the below contact details.

Email Address: PV_local_ROPU_MENA@boehringer-ingelheim.com

Mobile: +97155 9865722

Document Number: PC-AE-XXXXXX

Production Date: March 2024

Boehringer Ingelheim takes the protection of your personal data seriously and we have policies and procedures in place to protect your personal information, in order to comply with our internal Data Protection Standards as well as applicable Data Protection Laws.

As part of our continuous efforts to provide you with relevant scientific information pertaining to our product portfolio or relevant diseases estates we may collect personal data from you (e.g. business emails, telephone/mobile numbers, fax and postal addresses) and we may also disclose such personal data to Boehringer Ingelheim group companies globally and also to third parties who are involved in sending you information on behalf of Boehringer Ingelheim.

You may withdraw your consent at any time to the collection, use and disclosures of your personal data for the purposes stated above by contacting the Data Protection Officer at METAdataprotection.AE@boehringer-ingelheim.com or [click this link to Unsubscribe](#).

 Boehringer Ingelheim

Jardiance®
(empagliflozin)